Table 2.
Quality appraisal results of included studies.
| Study ID | Country | Level of Evidence | JBI Checklist | JBI Grade (Score) | Review Component |
|---|---|---|---|---|---|
| Ozturk 202116 | Turkey | II | RCT | I (11/13) | Qualitative |
| Greiner 202117 | Germany | III | Quasi-Experimental | I (9/9) | Qualitative |
| Kholinne 202018 | South Korea | III | Quasi-Experimental | I (8/9) | Qualitative & Quantitative |
| Kholinne 202119 | South Korea | III | Quasi-Experimental | I (9/9) | Qualitative |
| Lacheta 2020b20 | USA | III | Quasi-Experimental | I (8/9) | Qualitative |
| Mihata 201821 | Japan | III | Cohort Study | I (11/11) | Qualitative |
| Mihata 202022 | Japan | III | Cohort Study | I (11/11) | Qualitative |
| Takayama 202023 | Japan | III | Cohort Study | I (11/11) | Qualitative |
| Takayama 202124 | Japan | III | Cohort Study | I (9/11) | Qualitative |
| Denard 20188 | USA | IV | Case Series | I (9/10) | Qualitative |
| Evuarherhe 202226 | USA | IV | Case Series | I (10/10) | Qualitative |
| Gilat 202127 | USA | IV | Case Series | I (9/10) | Qualitative |
| LaBelle 202125 | USA | III | Cohort Study | I (10/11) | Quantitative |
| Baek 202128 | South Korea | IV | Case Series | I (9/10) | Quantitative |
| Lacheta 2020a29 | USA | IV | Case Series | I (9/10) | Quantitative |
| Lee 201830 | South Korea | IV | Case Series | I (9/10) | Quantitative |
| Lim 201931 | South Korea | IV | Case Series | I (9/10) | Quantitative |
| Shin 202232 | South Korea | IV | Case Series | I (10/10) | Quantitative |